Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

References

• Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587–95. doi:10.1586/era.09.25. PMID:19445576.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Liu W, Gotlieb V. The rapidly evolving therapies for advanced melanoma-Towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2016;99:91–9. doi:10.1016/j.critrevonc.2015.12.002.
   Web of Science ®Google Scholar
• Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, et al. Melanoma. Nature reviews Disease primers. 2015;1:15003. doi:10.1038/nrdp.2015.3. PMID:27188223.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54. doi:10.1038/nature00766. PMID:12068308.
   PubMed Web of Science ®Google Scholar
• Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, Kloxin AM, Maverakis E. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther. 2016;10:43–52. PMID:26730180.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov. 2011;10:811–2. doi:10.1038/nrd3579. PMID:22037033.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012;366:707–14. doi:10.1056/NEJMoa1112302. PMID:22356324.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Mitsiades N. B-Raf Inhibition in the Clinic: Present and Future. Annu Rev Med. 2016;67:29–43. doi:10.1146/annurev-med-090514-030732. PMID:26768236.
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18:1386–94. doi:10.1158/1078-0432.CCR-11-2479. PMID:22156613.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225–31. doi:10.1158/1078-0432.CCR-12-1630. PMID:23307859.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014;2:643–54. doi:10.1158/2326-6066.CIR-13-0215. PMID:24903021.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013;1:373–7. doi:10.1158/2326-6066.CIR-13-0092. PMID:24490176.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England journal of medicine. 2013;368:1365–6. doi:10.1056/NEJMc1302338. PMID:23550685.
   PubMed Web of Science ®Google Scholar
• Ferrari de Andrade L, Ngiow SF, Stannard K, Rusakiewicz S, Kalimutho M, Khanna KK, Tey SK, Takeda K, Zitvogel L, Martinet L, et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 2014;74:7298–308. doi:10.1158/0008-5472.CAN-14-1339. PMID:25351955.
   PubMed Web of Science ®Google Scholar
• Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013;123:1371–81. doi:10.1172/JCI66236. PMID:23454771.
   PubMed Web of Science ®Google Scholar
• Mendez R, Aptsiauri N, Del Campo A, Maleno I, Cabrera T, Ruiz-Cabello F, Garrido F, Garcia-Lora A. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer immunology, immunotherapy: CII. 2009;58:1507–15. doi:10.1007/s00262-009-0701-z. PMID:19340423.
   PubMed Web of Science ®Google Scholar
• Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrors B, Bicker A, Lindemann M, Roesch A, Gaudernack G, et al. Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Cancer Res. 2016;76:4347–58. doi:10.1158/0008-5472.CAN-16-0008. PMID:27261508.
   PubMed Web of Science ®Google Scholar
• Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 2017;222:11–20. doi:10.1016/j.imbio.2015.07.012. PMID:26264743.
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009;119:1251–63. doi:10.1172/JCI36022. PMID:19349689.
   PubMed Web of Science ®Google Scholar
• Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer immunology, immunotherapy: CII. 2009;58:1517–26. doi:10.1007/s00262-009-0682-y. PMID:19259667.
   PubMed Web of Science ®Google Scholar
• Tarazona R, Duran E, Solana R. Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Frontiers in immunology. 2015;6:649. PMID:26779186.
   PubMed Web of Science ®Google Scholar
• Molfetta R, Quatrini L, Santoni A, Paolini R. Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis. Int J Mol Sci. 2017;18. doi:10.3390/ijms18081677. PMID:28767057.
   PubMed Web of Science ®Google Scholar
• Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer science 2017. doi:10.1111/cas.13324.
   Web of Science ®Google Scholar
• Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, Couturaud B, Girod A, Sastre-Garau X, Albert S, et al. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 2014;74:81–92. doi:10.1158/0008-5472.CAN-13-1303. PMID:24225017.
   PubMed Web of Science ®Google Scholar
• Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, et al. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nature communications. 2014;5:5639. doi:10.1038/ncomms6639. PMID:25472612.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016;5:e1136044. doi:10.1080/2162402X.2015.1136044. PMID:27141370.
   PubMed Web of Science ®Google Scholar
• Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, et al. Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib. Cancer Immunol Res. 2017;5:582–93. doi:10.1158/2326-6066.CIR-16-0380. PMID:28576831.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PloS one. 2007;2:e236. doi:10.1371/journal.pone.0000236. PMID:17311103.
   PubMed Web of Science ®Google Scholar
• Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178–86. PMID:12414645.
   PubMed Web of Science ®Google Scholar
• Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, et al. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol. 2016;46:409–19. doi:10.1002/eji.201445289. PMID:26564811.
   PubMed Web of Science ®Google Scholar
• Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321–9. doi:10.1158/0008-5472.CAN-04-4252. PMID:16024634.
   PubMed Web of Science ®Google Scholar
• Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005;65:11136–45. doi:10.1158/0008-5472.CAN-05-0599. PMID:16322264.
   PubMed Web of Science ®Google Scholar
• Vales-Gomez M. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. J Immunol. 2008;68:1546–54.
   Google Scholar
• Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. J Immunol. 2009;182:6600–9. doi:10.4049/jimmunol.0801214.
   PubMed Web of Science ®Google Scholar
• Chavez-Blanco A, De la Cruz-Hernandez E, Dominguez GI, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, Chacón-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol. 2011;39:1491–9. PMID:21805029.
   PubMed Web of Science ®Google Scholar
• West AC, Smyth MJ, Johnstone RW. The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology. 2014;3:e27414. doi:10.4161/onci.27414. PMID:24701376.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30–9. doi:10.1172/JCI69738. PMID:24382387.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16:7–19. doi:10.1038/nrc.2015.5. PMID:26694935.
   PubMed Web of Science ®Google Scholar
• Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, et al. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer. 2009;124:1594–604. doi:10.1002/ijc.24098. PMID:19089914.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA, Zwirner NW. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol. 2008;180:4606–14. doi:10.4049/jimmunol.180.7.4606.
   PubMed Web of Science ®Google Scholar
• Garcia-Cuesta EM, Lopez-Cobo S, Alvarez-Maestro M, Esteso G, Romera-Cardenas G, Rey M, Cassady-Cain RL, Linares A, Valés-Gómez A, Reyburn HT, et al. NKG2D is a Key Receptor for Recognition of Bladder Cancer Cells by IL-2-Activated NK Cells and BCG Promotes NK Cell Activation. Frontiers in immunology. 2015;6:284. PMID:26106390.
   PubMed Web of Science ®Google Scholar
• Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3:602–9. doi:10.1158/2326-6066.CIR-15-0030. PMID:25795007.
   PubMed Web of Science ®Google Scholar
• Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol. 2012;189:1826–34. doi:10.4049/jimmunol.1200965.
   PubMed Web of Science ®Google Scholar
• Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering. Cancer Res. 2014;74:68–80. doi:10.1158/0008-5472.CAN-13-1186. PMID:24197135.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413–41. doi:10.1146/annurev-immunol-032712-095951. PMID:23298206.
   PubMed Web of Science ®Google Scholar
• Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. The Journal of experimental medicine. 2012;209:2409–22. doi:10.1084/jem.20120565. PMID:23166357.
   PubMed Web of Science ®Google Scholar
• Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186–90. doi:10.1038/nature03884. PMID:15995699.
   PubMed Web of Science ®Google Scholar
• Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A. The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol. 2014;4:508. doi:10.3389/fimmu.2013.00508. PMID:24432022.
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. American journal of clinical and experimental immunology. 2014;3:43–56. PMID:24660121.
   PubMedGoogle Scholar
• Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013;6:ra7. doi:10.1126/scisignal.2003057. PMID:23362240.
   PubMed Web of Science ®Google Scholar
• Lai F, Jin L, Gallagher S, Mijatov B, Zhang XD, Hersey P. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Adv Pharmacol 2012;65:27–43. doi:10.1016/B978-0-12-397927-8.00002-6. PMID:22959022.
   PubMedGoogle Scholar
• Zou Y, Han M, Wang Z, Stastny P. MICA allele-level typing by sequence-based typing with computerized assignment of polymorphic sites and short tandem repeats within the transmembrane region. Hum Immunol. 2006;67:145–51. doi:10.1016/j.humimm.2006.02.016. PMID:16698436.
   PubMed Web of Science ®Google Scholar
• Mandelboim O, Reyburn HT, Vales-Gomez M, Pazmany L, Colonna M, Borsellino G, Strominger JL. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. The Journal of experimental medicine. 1996;184:913–22. doi:10.1084/jem.184.3.913. PMID:9064351.
   PubMed Web of Science ®Google Scholar
• Vales-Gomez M, Winterhalter A, Roda-Navarro P, Zimmermann A, Boyle L, Hengel H, Brooks A, Reyburn HT. The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope. Cell Microbiol. 2006;8:581–90. doi:10.1111/j.1462-5822.2005.00645.x. PMID:16548884.
   PubMed Web of Science ®Google Scholar
• Perez-Villar JJ, Melero I, Navarro F, Carretero M, Bellon T, Llano M, Colonna M, Geraghty DE, López-Botet M. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol. 1997;158:5736–43.
   PubMed Web of Science ®Google Scholar